Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals

Luke Blagdon Snell, Prijay Bakrania, Tom G.S. Williams, Jerry Tam, Dayana Da Silva Fontoura, Emily Shaw, Anna Daunt, Jonathan Edgeworth, Carolyn J. Hemsley, Paul Fields, Sangita Agarwal, Boris Lams, Helen Cahill, Iain Milligan, Alina Botgros, Gaia Nebbia, Sam Douthwaite, Emma J. Aarons

Research output: Contribution to journalArticle

134 Downloads (Pure)

Abstract

We report the use of combination therapy with remdesivir and nirmatrelvir/ritonavir (Paxlovid) in successfully treating severe, chronic COVID-19 caused by persistent SARS-CoV-2 infection over 4 months. Other novel aspects include extended courses of treatment for 10 days and crushing of nirmatrelvir to allow administration via an NG tube. This case demonstrates potential synergy between remdesivir and nirmatrelvir/ritonavir (Paxlovid) in treating persistent, symptomatic SARS-CoV-2 infection.
Original languageEnglish
Journalpreprint
Publication statusAccepted/In press - 1 Nov 2022

Cite this